Search Result

Results for "

ain

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Aurora Kinase (1) Bacterial (1) Carboxylesterase (CES) (1) Casein Kinase (2) DNA Methyltransferase (1) DNA/RNA Synthesis (1) Drug Derivative (1) DYRK (12) Enterovirus (1) Epigenetic Reader Domain (2) GSK-3 (1) HCV Protease (4) Histone Acetyltransferase (2) Histone Demethylase (2) Histone Methyltransferase (2) Interleukin Related (2) IRE1 (2) Isotope-Labeled Compounds (1) Kinesin (13) Liposome (1) Methionine Adenosyltransferase (MAT) (16) Microtubule/Tubulin (10) Phosphatase (1) Phosphodiesterase (PDE) (6) Potassium Channel (1) PROTACs (1) Reactive Oxygen Species (1) Somatostatin Receptor (3) Trk Receptor (1) Wnt (2)
By Research Areas:	Cancer (50) Cardiovascular Disease (1) Infection (9) Inflammation/Immunology (7) Metabolic Disease (5) Neurological Disease (10)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9927

Secukinumab 2 Publications Verification ain457	Interleukin Related	Inflammation/Immunology Cancer
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-145803

KIF18A-IN-3	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-3 is a potent KIF18A inhibitor (IC₅₀=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer .

HY-145802

KIF18A-IN-2	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-2 is a potent KIF18A inhibitor (IC₅₀=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer .

HY-146221

Dyrk1A-IN-5 1 Publications Verification	DYRK	Neurological Disease
Dyrk1A-IN-5 (compound 5j) is a potent and selective DYRK1A inhibitor, with an IC₅₀ of 6 nM. Dyrk1A-IN-5 dose-dependently reduces the phosphorylation of Thr434 in SF3B1, with an IC₅₀ of 0.5 μM. Dyrk1A-IN-5 inhibits phosphorylation of tau at Thr212, with an IC₅₀ of 2.1 μM. Dyrk1A-IN-5 can be used for Down syndrome research .

HY-170500

MAT2A-IN-17	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-17 is a potent MAT2A inhibitor with an IC₅₀ < 100 nM. MAT2A-IN-17 can be used in the study of cancer .

HY-170503

MAT2A-IN-20	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-20 (Compound A49) is an inhibitor for methionine adenosyltransferase 2A (MAT2A) with an IC₅₀ ≤50 nM. MAT2A-IN-20 inhibits human UGT1A1 with an IC₅₀ of 28.45 μM. MAT2A-IN-20 exhibits antitumor in mouse models .

HY-158237

PDE10A-IN-3	Phosphodiesterase (PDE)	Neurological Disease
PDE10A-IN-3 (Compound 8a) is an inhibitor of phosphodiesterase 10A (PDE10A). PDE10A-IN-3 can be used in schizophrenia research .

HY-170905S

MAT2A-IN-22	Methionine Adenosyltransferase (MAT) Isotope-Labeled Compounds	Cancer
MAT2A-IN-22 (Compound 29-1) is a BBB-penatrable and orally active MAT2A inhibitor with an IC₅₀ of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects .

HY-158757

KIF18A-IN-12	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-12 (compound 9) is a KIF18A inhibitor, with an IC₅₀ value of 45.54 nM. KIF18A-IN-12 can be used in cancer research .

HY-149915

MAT2A-IN-10	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-10 (Compound 28) is an orally active MAT2A inhibitor with an IC₅₀ of 26 nM. MAT2A-IN-10 can be used for the research of cancer .

HY-158212

Dyrk1A-IN-8	DYRK	Neurological Disease
Dyrk1A-IN-8 (compound 4C) is a potent inhibitor of Dyrk1A , with the IC₅₀ of 209 nM. Dyrk1A-IN-8 plays an important role in neurodegenerative diseases .

HY-170940

Dyrk1A-IN-12	DYRK Enterovirus	Infection
Dyrk1A-IN-12 (compound S43) is a Dyrk (Dual specificity tyrosine phosphorylation regulated kinase 1A inhibitor. Dyrk1A-IN-12 inhibits Dyrk1A with a IC₅₀ of 95 nM. Dyrk1A-IN-12 shows anti-EV-A71 activity with an EC₅₀ of 4.4 μM, CC₅₀ of 12.8 μM and SI of 2.9. Dyrk1A-IN-12 shows potent inhibition against herpes simplex virus (HSV) .

HY-131973

PDE10A-IN-2 hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease Metabolic Disease
PDE10A-IN-2 hydrochloride is a potent, highly selective and orally active phosphodiesterase 10A (PDE10A) inhibitor with an IC₅₀ of 2.8 nM. PDE10A-IN-2 hydrochloride shows selectivity of >3500-fold against other PDE subtypes. PDE10A-IN-2 hydrochloride can be used for pulmonary arterial hypertension (PAH) research .

HY-162010

MAT2A-IN-13	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-13 is a potent and orally active methionine adenosyltransferase 2A (MAT2A) inhibitor with a favorable pharmacokinetic profile. MAT2A-IN-13 shows in vivo potency in an HCT-116 MTAP-deleted xenograft model. MAT2A-IN-13 can be used for MTAP-Deleted tumors treatment research .

HY-157478

CSNK2A-IN-1	Casein Kinase	Infection
CSNK2A-IN-1 (compound 7C) is a selective CSNK2A inhibitor. CSNK2A-IN-1 has antiviral activity and improved selectivity over PIM3 .

HY-162937

KIF18A-IN-13	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-13 (Compound 16) is an effective and orally active inhibitor of KIF18A with anticancer activity in vivo. KIF18A-IN-13 can be utilized for research in ovarian cancer .

HY-170832

Menin–KMT2A-IN-1	Epigenetic Reader Domain Potassium Channel	Cancer
Menin–KMT2A-IN-1 (Compound 20) is the inhibitor for menin–KMT2A that binds to menin with an IC₅₀ of 8 nM, and inhibits the interaction between menin and lysine methyltransferase 2A (KMT2A). Menin–KMT2A-IN-1 inhibits hERG with an IC₅₀ of 65 μM. Menin–KMT2A-IN-1 inhibits cell MV4-11 with an IC₅₀ of 74 nM. Menin–KMT2A-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mouse with an orally bioavailability of 74% .

HY-158393

IRE1a-IN-2	IRE1	Cancer
IRE1a-IN-2 (Compound 30) is an IRE1α inhibitor, with an IC₅₀ of over than 200 nM for XBP1 mRNA. IRE1a-IN-2 can be used for the research of cancer .

HY-158386

IRE1a-IN-1	IRE1	Cancer
IRE1a-IN-1 (Compound 10) is an IRE1α inhibitor, with an IC₅₀ of less than 100 nM for XBP1 mRNA. IRE1a-IN-1 can be used for the research of cancer .

HY-168445

MAT2A-IN-21	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-21 (compound 28) is a potent methionine adenosyltransferase 2A (MAT2A) inhibitor with an IC₅₀ of 49 nM. MAT2A-IN-21 selectivity inhibits MTAP-deficient cancer cells .

HY-163182

CSNK2A-IN-2	Casein Kinase	Infection
CSNK2A-IN-2 (compound 6c) is a selective CSNK2A inhibitor with antiviral activity. CSNK2A-IN-2 exhibits an inhibitory effect on viral replication and is selective for PIM3 .

HY-164980

KIF18A-IN-16	Kinesin	Cancer
KIF18A-IN-16 (Compound 15) is a fused ring KIF18A inhibitor. KIF18A-IN-16 can be used in oncology (e.g., colon, breast, lung cancer) studies .

HY-145827

KIF18A-IN-4	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-4 is a moderately potent ATP and microtubule (MT) noncompetitive KIF18A inhibitor (IC₅₀=6.16 μM). KIF18A-IN-4 has selectivity against a large panel of mitotic kinesins and kinases, and does not show any direct effects on tubulin assembly. KIF18A-IN-4 exhibits anti-tumor activity .

HY-161787

G9a-IN-2	Histone Methyltransferase	Others
G9a-IN-2 (Compound 7i) is an inhibitor for histone methyltransferases G9a with IC₅₀ of 0.024 μM. G9a-IN-2 reduces H3K9me2 levels and induces the mRNA expression of γ-globin mRNA. G9a-IN-2 shows the potential in ameliorating sickle cell disease (SCD) .

HY-145034

KIF18A-IN-1 1 Publications Verification	Kinesin Microtubule/Tubulin	Inflammation/Immunology Cancer
KIF18A-IN-1 is a mitotic kinesin KIF18A inhibitor extracted from patent WO2021026098A1 example 100-13. KIF18A-IN-1 exhibits anti-tumor activity .

HY-144179

MAT2A-IN-4	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-4 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1 compound 426 . MAT2A-IN-4 can be used for the research of cancer .

HY-162107

Dyrk1A-IN-6	DYRK	Neurological Disease
Dyrk1A-IN-6 (compound 7cc) is an EGCG-like non-competitive inhibitor of DYRK1A. Dyrk1A-IN-6 can be used to alleviate cognitive defects in Down syndrome models .

HY-170906S

MAT2A-IN-23	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

HY-115982

NS5A-IN-3	HCV Protease	Infection
NS5A-IN-3 (Compound 15) is a potent inhibitor of NS5A. NS5A-IN-3 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability. NS5A-IN-3 exhibits a higher resistance barrier than daclatasvir against genotype 1b . NS5A-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147066

Dyrk1A-IN-4	DYRK	Cancer
Dyrk1A-IN-4 (compound 48) is a potent and orally active DYRK1A and DYRK2 inhibitor with IC₅₀s of 2 nM and 6 nM, respectively. Dyrk1A-IN-4 has anticancer effects .

HY-147760

Dyrk1A-IN-2	DYRK	Metabolic Disease
Dyrk1A-IN-2 (Compound 63) is a DYRK1A inhibitor with an EC₅₀ of 37 nM. Dyrk1A-IN-2 exhibits highly potent human β-cell replication-promoting activity and low cytotoxicity .

HY-144184

MAT2A-IN-6	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .

HY-144185

MAT2A-IN-7	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .

HY-141890

BAZ1A-IN-1	Epigenetic Reader Domain	Cancer
BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a K_D value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A, but weak or no activity against cancer cells with a low expression level of BAZ1A .

HY-144181

MAT2A-IN-5	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .

HY-142929

MAT2A-IN-2	Somatostatin Receptor	Cancer
MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .

HY-142928

MAT2A-IN-1	Somatostatin Receptor	Cancer
MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .

HY-142930

MAT2A-IN-3	Somatostatin Receptor	Cancer
MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .

HY-159496

Dyrk1A-IN-10	DYRK	Metabolic Disease
Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .

HY-158683

KIF18A-IN-11	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-11 (Compound 13) is a potent KIF18A inhibitor, with IC₅₀ values of less than 100 nM in OVCAR3 and MDA-MB-157 cells. KIF18A-IN-11 can be used for the research of cancer .

HY-158159

IL17A-IN-1	Interleukin Related	Inflammation/Immunology Cancer
IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .

HY-144433

DNMT3A-IN-1 1 Publications Verification	DNA Methyltransferase	Infection
DNMT3A-IN-1 (compound 1) is an effective and selective DNMT3A inhibitor. DNMT3A-IN-1 exhibits inhibitory activity against DNMT3A, with K_I values ranging from 9.16 to 18.85 μM (AdoMet) and 11.37 to 23.34 μM (poly dI-dC). DNMT3A-IN-1 can induce apoptosis in acute myeloid leukemia (AML) cell lines (Apoptosis) .

HY-115981

NS5A-IN-2	HCV Protease	Infection
NS5A-IN-2 (Compound 33) is a potent inhibitor of NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability . NS5A-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-155228

LK-44	Others	Inflammation/Immunology
hCES2A-IN-2 (Compound 44) is an orally active human carboxylesterase 2 (hCES2A) inhibitor (IC₅₀: 5.02 μM). hCES2A-IN-2 improves Irinotecan (HY-16562)-induced delayed diarrhea .

HY-155755

hCES2A-IN-1	Carboxylesterase (CES) Drug Derivative	Cancer
hCES2A-IN-1 (compound 20w) is a potent hCES2A inhibitor, with an IC₅₀ value of 1.6 nM. hCES2A-IN-1, a bysspectin A derivative, shows an approximately 1000-fold improvement over the lead compound bysspectin A .

HY-162994

KAT6A-IN-1	Histone Acetyltransferase	Cancer
KAT6A-IN-1 (compund 5) is a KAT6A inhibitor .

HY-161298

MAT2A-IN-15	Methionine Adenosyltransferase (MAT)	Cancer
MAT2A-IN-15 (compound 8) is an inhibitor of MAT2A .

HY-162995

KAT6A-IN-2	Histone Acetyltransferase	Cancer
KAT6A-IN-2 (compund 7) is a KAT6A inhibitor .

HY-162532

KIF18A-IN-10	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-10 (Compound 24) is a potent KIF18A inhibitor, with an IC₅₀ value of 23.8 nM. KIF18A-IN-10 has anticancer activity, with IC₅₀ values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .

HY-162531

KIF18A-IN-9	Kinesin Microtubule/Tubulin	Cancer
KIF18A-IN-9 (Compound 1) is a potent KIF18A inhibitor, with an IC₅₀ value of 3.8 nM. KIF18A-IN-9 has anticancer activity, with IC₅₀ values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .

Cat. No.	Product Name	Type

HY-W099547

Dihexadecyl hydrogen phosphate

Biochemical Assay Reagents

Dihexadecyl hydrogen phosphateIt is an organic compound belonging to phospholipids. It's often used as an emulsifier, which means it helps mix two substances together that don't usually mix well, such as oil and water. Dihexadecyl hydrogen phosphateIt has several applications in the food industry, especially in the production of processed foods where it improves texture and stability. Additionally, it has applications in the pharmaceutical industry where it can be used ain the generation of micelles, liposomes, and other types of artificial membranes.

Cat. No.	Product Name	Target	Research Area

HY-P9927

Secukinumab 2 Publications Verification ain457	Interleukin Related	Inflammation/Immunology Cancer
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .

Cat. No.	Product Name	Chemical Structure

HY-170905S

MAT2A-IN-22
MAT2A-IN-22 (Compound 29-1) is a BBB-penatrable and orally active MAT2A inhibitor with an IC₅₀ of 4 nM. MAT2A-IN-22 shows selectivity and inhibitory activity against MTAP-deficient cancer cell lines. MAT2A-IN-22 has anti-tumor effects .

HY-170906S

MAT2A-IN-23

MAT2A-IN-23 (compound 39) is a MAT2A inhibitor, with an IC₅₀ of 4 nM. MAT2A-IN-23 inhibits SAM in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 3 and 2 nM, respectively. MAT2A-IN-23 inhibits SDMA in the HCT-116 (MTAP ^−/−) and in the HCT-116 WT cell line with IC₅₀s of 2 and >3000 nM, respectively. MAT2A-IN-23 inhibits HCT-116 (MTAP ^−/−) cell proliferation with with an IC₅₀ of 47 nM .

Cat. No.	Product Name		Classification

HY-162994

KAT6A-IN-1		Alkynes
KAT6A-IN-1 (compund 5) is a KAT6A inhibitor .

Cat. No.	Product Name		Classification

HY-W099547

Dihexadecyl hydrogen phosphate		Phospholipids
Dihexadecyl hydrogen phosphateIt is an organic compound belonging to phospholipids. It's often used as an emulsifier, which means it helps mix two substances together that don't usually mix well, such as oil and water. Dihexadecyl hydrogen phosphateIt has several applications in the food industry, especially in the production of processed foods where it improves texture and stability. Additionally, it has applications in the pharmaceutical industry where it can be used ain the generation of micelles, liposomes, and other types of artificial membranes.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: